UroGen Pharma-Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates

Urogen Pharma (URGN) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of$ 0.74. This compares to loss of $0.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -8.11%. A quarter ago, it was expected that this company would post a loss of$ 0.84 per share when it actually produced a loss of $0.55, delivering a surprise of 34.52%.Over the last four quarters, the company has surpassed ...